Nasal Decongestant Use in School-Age Children

Age-Specific Safety Considerations

The FDA's Nonprescription Drugs and Pediatric Advisory Committees recommended in 2007 that OTC cough and cold medications, including decongestants, should not be used in children below 6 years of age due to documented fatalities and lack of proven efficacy. 1, 2
Between 1969 and 2006, there were 54 fatalities associated with decongestants (including oxymetazoline) in children under 6 years. 1

Rebound congestion (rhinitis medicamentosa) can develop as early as the third or fourth day of continuous oxymetazoline use. 1
The package insert for Afrin specifically recommends use for no more than 3 days. 1
Continued use of oxymetazoline beyond 3 days leads to a paradoxical worsening of nasal obstruction, creating a cycle of dependency. 1
Oxymetazoline works through vasoconstriction of nasal blood vessels, but with ongoing use, the decongestive action lessens while nasal obstruction paradoxically increases. 1

Intranasal corticosteroids (like fluticasone) are the most effective medication class for controlling nasal congestion in children and do NOT cause rebound congestion. 1, 2
Intranasal corticosteroids are safe and effective for long-term use in children. 1, 2
Intranasal corticosteroids have an onset of action of 3-12 hours, with maximum benefit achieved in several days. 2

When immediate relief is needed, oxymetazoline can be applied first, followed 5 minutes later by intranasal corticosteroid application, allowing the decongestant to open nasal passages for better steroid penetration. 3
When using combination therapy, oxymetazoline should be limited to 1-2 days maximum while continuing the intranasal steroid. 3

Oral decongestants and antihistamines should not be used as alternatives in school-age children as they are less effective and carry their own risks. 1, 2
Multiple OTC cold medications should not be used simultaneously as this increases toxicity risk in children. 1